Hill Stephen J. 4
4 · Lyell Immunopharma, Inc. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
Hill Stephen J.
Chief Operating Officer
Transactions
- Award
Common Stock
2024-02-09+40,000→ 48,928 total - Award
Stock Option (right to buy)
2024-02-09+400,000→ 400,000 totalExercise: $1.80Exp: 2034-02-08→ Common Stock (400,000 underlying)
Footnotes (3)
- [F1]The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Includes 2,941 shares acquired on May 18, 2022, 5,434 shares acquired on May 18, 2023 and 553 shares acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan.
- [F3]12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.